LONGBIO-B (01779): Recommend adopting H-share stock purchase rights plan and H-share equity incentive plan.

date
06:49 16/07/2026
avatar
GMT Eight
Tianchen Biopharmaceuticals-B (01779) announced that on July 15, 2026, the board of directors has decided to recommend adopting the company's H-share subscription plan and H-share stock incentive plan.
LONGBIO-B (01779) announced that on July 15, 2026, the Board of Directors has proposed to adopt the company's H-share option scheme and H-share incentive scheme. The H-share option scheme and H-share incentive scheme aim to establish and improve the company's long-term incentive mechanism, attract and retain key talents to drive business growth, and align the interests of shareholders, the company, and employees; commit to implementing a comprehensive strategy covering research and development, clinical development, and commercialization to promote the company's business transformation and value enhancement; promote cooperation to achieve a collaborative, shared, and win-win future; and promote the realization of the company's long-term strategic and performance goals. The share scheme is expected to provide the company with flexible means to retain, reward, compensate eligible individuals, and/or provide incentives to them. The company's H-shares involved in the options granted under the H-share option scheme will be fulfilled by issuing and distributing new H-shares and/or transferring the company's treasury shares (if any). The H-shares involved in the share incentives granted under the H-share incentive scheme shall be purchased by the designated trustee through the following methods: (i) purchasing new H-shares from the company at face value; (ii) using the plan funds to purchase in the secondary market at the prevailing market price; and/or (iii) using the company's treasury shares (if any). The maximum number of H-shares that can be issued and distributed or transferred from the treasury for all options and share incentives granted under the H-share option scheme and H-share incentive scheme, as well as for all options and share incentives granted under any other share scheme of the company, shall not exceed 10% of the total number of issued shares of the company on the day when the shareholders approve the scheme (excluding treasury shares, if any).